Galapagos | GLPG - Equity Capital And Reserves


Galapagos reported EUR3.24B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
argenx SE USD 6.1B 597.47M Jun/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
Genmab DKK 5.85B 96M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
GRIFOLS EUR 5.29B 108.05M Dec/2025
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Merck EUR 28.59B 344M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novartis USD 46.13B 1.38B Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 71.71B 1.55B Dec/2025
UCB EUR 10.87B 1.18B Dec/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025